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and other electroconvulsive disorders by administering a 
pharmaceutically effective amount of a therapeutic com 
pound having the following formula (1): 
Embodiments include administering an effective amount of 
4,4'-thiodianiline, 4,4'-diaminobenZophenone, 4,4'-methyl 
enedianiline, 4,4'-diaminodiphenyl ether, or (3-aminophe 
nyl)-(4-aminophenyl) amine, an analog, or a pharrnaceuti 
cally accepted salt or complex thereof to a mammal in need 
of treatment or prevention of epilepsy, seizure, or other 
electroconvulsive disorder. 
11 Claims, No Drawings 
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COMPOUNDS OF USE IN THE TREATMENT 
OF EPILEPSY, SEIZURE, AND 
ELECTROCONVULSIVE DISORDERS 
RELATED APPLICATIONS 
This application is a divisional of application Ser. No. 
10/345,387 ?led Jan. 16, 2003 noW abandoned. 
This application claims the bene?t of US. Provisional 
Patent Application No. 60/348,366 ?led Jan. 16, 2002, 
Which is incorporated herein by reference. 
FIELD OF THE INVENTION 
The present invention relates to bridged dianilino com 
pounds and pharmaceutical compositions and method of use 
thereof for the prevention and treatment of epilepsies, sei 
zures, and other electroconvulsive disorders. Speci?cally, 
this invention relates to the use of 4,4'-thiodianiline, 4,4' 
diaminobenzophenone, 4,4'-methylenedianiline, 4,4'-diami 
nodiphenyl ether, or (3-aminophenyl)-(4-aminophenyl) 
amine and related compounds, and preparations thereof, for 
the prevention, palliation and/or treatment of seizures, con 
duction disturbances and electroconvulsive disorders of all 
types, manifestations and origins, in humans and in animals. 
BACKGROUND OF THE INVENTION 
Epilepsy is a general term describing a group of central 
nervous system disorders that are characterized by recurrent 
seizures that are the outWard manifestation of excessive 
and/or hyper-synchronous abnormal electrical activity of 
neurons of the cerebral cortex and other regions of the brain. 
This abnormal electrical activity can be manifested as motor, 
convulsion, sensory, autonomic, or psychic symptoms. 
Epilepsy affects millions of people WorldWide, and over 
2.5 million individuals in the United States. For the purposes 
of clinical assessment, it is useful to classify patients accord 
ing to the type of seizure the patient experiences. As 
described in The Pharmacological Basis ofTherapeuZics, 9th 
Ed. (McGraW-Hill) [1], there are tWo classes of seizures: 
partial seizures and generalized seizures. Partial seizures 
consist of focal and local seizures. Partial seizures are 
further classi?ed as simple partial seizures, complex partial 
seizures and partial seizures secondarily generalized. Gen 
eralized seizures are classi?ed as convulsive and noncon 
vulsive seizures. They are further classi?ed as absence 
(previously referred to as ‘petit mal’) seizures, atypical 
absence seizures, myoclonic seizures, clonic seizures, tonic 
seizures, tonic-clonic seizures, and atonic seizures. 
Hundreds of epileptic syndromes have been de?ned as 
disorders characterized by speci?c symptoms that include 
epileptic seizures. These include, but are not limited to, 
absence epilepsy, psychomotor epilepsy, temporal lobe epi 
lepsy, frontal lobe epilepsy, occipital lobe epilepsy, parietal 
lobe epilepsy, Lennox-Gastaut syndrome, Rasmussen’s 
encephalitis, childhood absence epilepsy, Ramsay Hunt 
Syndrome type II, benign epilepsy syndrome, benign infan 
tile encephalopathy, benign neonatal convulsions, early 
myoclonic encephalopathy, progressive epilepsy and infan 
tile epilepsy. A patient may suffer from any combination of 
different types of seizures. Partial seizures are the most 
common, and account for approximately 60% of all seizure 
types. Regardless of the type of epilepsy, seizures signi? 
cantly limit the autonomy of the patient. 
It is believed that the characteristic seizures of epilepsy 












?ring of brain neurons. The neurons can ?re at up to four 
times their normal rate. As a result, epileptic seizures are an 
overstimulation of the normal neuronal processes that con 
trol brain function. 
Anti-epileptic drugs are available for treating epilepsies, 
but these agents have a number of shortcomings. For 
instance, the agents are often poorly soluble in aqueous and 
biological ?uids or are extremely hygroscopic. Of even 
greater importance is that patients often become refractory 
to a drug over time. In addition, many anti-epileptic agents 
cause unWanted side effects, neurotoxicities, and drug inter 
actions. Even While being treated With one or a combination 
of the anti-epileptic drugs currently in clinical use, 30% of 
epileptic patients still experience seizures. As more anti 
epileptic drugs are developed, the clinician Will have 
expanded pharmaceutical options When designing an effec 
tive treatment protocol for each patient. Accordingly, a 
continuing need exists for pharmaceutical compositions that 
treat or prevent epilepsy and its associated symptoms With 
minimal side effects. 
After experimentation and investigation, it has been dis 
covered that oral and intraperitoneal administration of a 
therapeutic compound comprising formula (I) beloW to mice 
and rats resulted in profound and reproducible anticonvul 
sant or antiepileptic activity in animal modes of seizure 
disorders. It has further been discovered that these com 
pounds do not shoW acute neurotoxic effects at the levels 
required for a therapeutic response. 
SUMMARY OF THE INVENTION 
An advantage and object of the present invention is a 
pharmaceutical composition useful for the treatment, pre 
vention and/or amelioration of disorders related to and 
including epilepsy, seizure, and other electroconvulsive dis 
orders. 
According to the present invention, the foregoing objects 
and advantages are achieved in part by a therapeutic com 
pound, including resolved enantiomers, diastereoisomers, 
tautomers, salts, solvates and polymorphic forms thereof, 
having the folloWing formula (I): 
(1) 
Wherein R1, R2, R3, and R4, are each independently selected 
from the group consisting of hydrogen, hydroxy, amino, 
phenyl, a substituted or unsubstituted Cl_1O alkyl, C3_1O 
branched alkyl, a substituted or unsubstituted C3_8 
cycloalkyl, a substituted or unsubstituted arylalkyl, a sub 
stituted or unsubstituted C1_ 10 alkoxyl and a substituted or 
unsubstituted C1_ 10 acyl; and X is selected from the group 
consisting of 40*, iSi, iN(H)i, iSei, iSii, 
%H=CHi, 4CECi, iN=Ni, iN=CHi, 
%H=Ni, %(S)i, iN(H)S(O)i, iN(H)SO2i, 
iN(H)Oi, iN(H)Si, iS(O)i, iSOzi, iPO4i, 
iSi(O)i, iC(O)i, 4CH2i, 4CF2i, and a covalent 
bond. 
Another object of the present invention is a method of 
treating, ameliorating, or preventing epilepsy, seizure or 
electroconvulsive disorders in a subject in need thereof. In 
an embodiment of the present invention, the method com 
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prises administering an effective amount of 4,4'-thiodi 
aniline, 4,4'-diaminobenZophenone, 4,4'-methylenedi 
aniline, 4,4'-diaminodiphenyl ether, or (3-aminophenyl)-(4 
aminophenyl) amine, or a pharmaceutically acceptable salt 
or complex thereof to a subject in need of treatment, 
amelioration, or prevention of such disorders. 
Further according to the invention, the foregoing objects 
and advantages for the treatment or prevention of electro 
convulsive disorders are achieved by administering a phar 
maceutical composition comprising an effective amount of 
the therapeutic compound to mammals in an admixture With 
a pharmaceutically acceptable carrier, adjuvant or vehicle. 
Still further according to the invention, the foregoing 
objects and advantages for the treatment or prevention of 
electroconvulsive disorders are achieved by administering 
an effective amount of 4,4'-thiodianiline, 4,4'-diaminodiphe 
nyl ether, 4,4'-diaminobenZophenone, 4,4'-methylenedi 
aniline, or (3-aminophenyl)-(4-aminophenyl) amine, or a 
pharmaceutically acceptable salt or complex thereof and in 
a pharmaceutically accepted carrier, adjuvant or vehicle. 
Embodiments of the present invention include a pharma 
ceutical composition comprising a dose of about 0.1 mg/kg 
to 300 mg/kg of 4,4'-thiodianiline, 4,4'-diaminobenZophe 
none, 4,4'-methylenedianiline, 4,4'-diaminodiphenyl ether, 
or (3-aminophenyl)-(4-aminophenyl) amine or the equiva 
lent of its pharmaceutically acceptable salt. 
Additional advantages of the present invention Will 
become readily apparent to those skilled in the art from this 
folloWing detailed description. As Will be realiZed, the 
invention is capable of other and different embodiments, and 
its several details are capable of modi?cations in various 
obvious respects, all Without departing from the present 
invention. 
DESCRIPTION OF THE INVENTION 
The present invention relates to therapeutic bridged 
dianilino compounds and their pharmaceutical compositions 
and method of use thereof for the prevention and treatment 
of epilepsies, seizures, and other electroconvulsive disor 
ders. The therapeutic compound comprises a compound 
having the folloWing formula (I): 
Wherein R1, R2, R3, and R4, are each independently selected 
from the group consisting of hydrogen, hydroxy, amino, 
phenyl, substituted or unsubstituted Cl_l0 alkyl, C3_1O 
branched alkyl, substituted or unsubstituted C3_8 cycloalkyl, 
substituted or unsubstituted arylalkyl (comprising Ari 
(CH2)n; Where Ar is aromatic and n:0-l0) substituted or 
unsubstituted Cl_1O alkoxyl, substituted or unsubstituted 
C 1_ 1O acyl, Where the substituents are, but are not limited to, 
substituents selected from the group consisting of halogen, 
phenyl, thio, amino, hydroxyl, hydroxylamino, nitrile, car 
boxyl, amido, phosphate, sulfate, sulfonamide, nitroso, 
nitrone, aZido, imino, hydraZine, guanidino, oxyguanidino, 
methylguanidino, hydroxyguanidino, aminoguanidino, 
thioguanidino, amidino, oxyamidino, ureido, thioureido, 
thioamido, and nitro; and X is selected from the group 











iSi(O)i, iC(O)i, 4CH2i, 4CF2i, and a covalent 
bond 
In an embodiment of the present invention, 4,4'-thiodi 
aniline, 4,4'-diaminobenZophenone, 4,4'-methylenedi 
aniline, 4,4'-diaminodiphenyl ether, and (3-aminophenyl) 
(4-aminophenyl) amine are formulated into a 
pharmaceutical preparation comprising the active agent or a 
pharmaceutically acceptable salt or complex thereof and a 
pharmaceutically acceptable carrier. 
It has been discovered that the inventive compositions are 
useful in the prevention, palliation, and/or treatment of 
seiZures, conduction disturbances and electroconvulsive dis 
orders of all types and their manifestations irrespective of 
the origin of the ailment in a subject in need thereof 
including humans and other mammals. It is contemplated 
that the inventive compositions can be employed for pre 
venting and/or treating other conduction disturbances of the 
central nervous system (CNS), and the emotional, cognitive, 
and motor symptoms resulting there from. 
In an embodiment of the present invention, the inventive 
compositions are administered to a subject in need thereof to 
prevent or treat disturbances of the CNS, such as seiZure and 
electroconvulsion, of either or both an acute or chronic 
nature, of unknown origin or secondary to conditions such 
as, but not limited to: surgery, irradiation, or other manipu 
lation of the brain and/or CNS; alcohol, benZodiaZepine, 
barbiturate or other drug or chemical WithdraWal; exposure 
to epileptogenic drugs and/or chemicals; acute or chronic 
injury or trauma; stroke or cerebrovascular accident; fever; 
meningitis or other CNS in?ammation or infection; or 
electroconvulsive therapy. 
In practicing the present invention, the compound having 
formula (I) or a pharmaceutically acceptable salt or complex 
thereof is formulated into pharmaceutical compositions. In 
an embodiment of the present invention, 4,4'-thiodianiline, 
4,4'-diaminobenZophenone, 4,4'-diaminodiphenyl ether, 
4,4'-methylenedianiline, or (3-aminophenyl)-(4-aminophe 
nyl) amine are formulated into pharmaceutical compositions 
The compound of formula (I) includes all resolved enan 
tiomers, diastereoisomers, tautomers, salts, solvates and 
polymorphic forms thereof. Salt forms of 4,4'-thiodianiline, 
4,4'-diaminobenZophenone, 4,4'-diaminodiphenyl ether, 
4,4'-methylenedianiline, or (3-aminophenyl)-(4-aminophe 
nyl) amine include, but are not limited to the folloWing: 
inorganic acid addition salts such as hydrochloride, hydro 
bromide, sulfate, phosphate and nitrate; organic acid addi 
tion salts such as acetate, galactarate, propionate, succinate, 
lactate, glycolate, malate, tartrate, citrate, maleate, fumarate, 
methanesulfonate, salicylate, p-toluenesulfonate, benZene 
sulfonate, and ascorbate; salts With acidic amino acids such 
as aspartate and glutamate; the salts may in some cases by 
hydrates or solvates With alcohols and other solvents. Salt 
forms of 4,4'-thiodianiline, 4,4'-diaminobenZophenone, 4,4' 
methylenedianiline, or (3-aminophenyl)-(4-aminophenyl) 
amine, can be prepared by mixing the acid in a conventional 
solvent, With or Without alcohols or Water. 
The compounds of the present invention are useful in 
pharmaceutical compositions for systemic administration to 
mammals including humans as a single agent, or as a 
primary or adjunct agent With any other medication, chemi 
cal, drug or non-drug therapy, or combination thereof. 
The aforementioned administration of 4,4'-thiodianiline, 
4,4'-diaminobenZophenone, 4,4'-methylenedianiline, 4,4' 
diaminodiphenyl ether, or (3 -aminophenyl)-(4-aminophe 
nyl) amine, or pharmaceutically acceptable salts or com 
plexes thereof is to be employed acutely, or as a single dose, 
or administered intermittently, or on a regular schedule of 
US 7,226,949 B2 
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unspeci?ed duration, or by continuous infusion of unspeci 
?ed duration, by an acceptable route of administration 
including, but not limited to, the oral, buccal, intranasal, 
pulmonary, transdermal, rectal, vaginal, intradermal, intrath 
ecal, intravenous, intramuscular, and/or subcutaneous 
routes. 
The pharmaceutical preparations can be employed in unit 
dosage forms, such as tablets, capsules, pills, poWders, 
granules, suppositories, sterile and parenteral solutions, or 
suspensions, sterile and non-parenteral solutions or suspen 
sions, oral solutions or suspensions, oil in Water or Water in 
oil emulsions and the like, containing suitable quantities of 
an active ingredient. Topical application can be in the form 
of ointments, creams, lotions, jellies, sprays, douches, and 
the like. For oral administration either solid or ?uid unit 
dosage forms can be prepared With the compounds of 
Formula I. 
Either ?uid or solid unit dosage forms can be readily 
prepared for oral administration. For example, the com 
pounds can be mixed With conventional ingredients such as 
dicalciumphosphate, magnesium aluminum silicate, magne 
sium stearate, calcium sulfate, starch, talc, lactose, acacia, 
methylcellulose and functionally similar materials as phar 
maceutical excipients or carriers. A sustained release for 
mulation may optionally be used. Capsules may be formu 
lated by mixing the compound With a pharmaceutical diluent 
Which is inert and inserting this mixture into a hard gelatin 
capsule having the appropriate siZe. If soft capsules are 
desired, a slurry (or other dispersion) of the compound, With 
an acceptable vegetable, light petroleum or other inert oil 
can be encapsulated by machine into a gelatin capsule. 
Suspensions, syrups, and elixirs may be used for oral 
administration of ?uid unit dosage forms. A ?uid preparation 
including oil may be used for oil soluble forms. A vegetable 
oil, such as corn oil, peanut oil, or sal?oWer oil, for example, 
together With ?avoring agents, sWeeteners, and any preser 
vatives produces an acceptable ?uid preparation. A surfac 
tant may be added to Water to form syrup for ?uid dosages. 
Hydro-alcoholic pharmaceutical preparations may be used 
that have an acceptable sWeetener, such as sugar, saccharine, 
or a biological sWeetener and a ?avoring agent in the form 
of an elixir. 
Pharmaceutical compositions for parental and suppository 
administration can also be obtained using techniques stan 
dard in the art. Another preferred use of these compounds is 
in a transdermal parenteral pharmaceutical preparation in a 
mammal such as a human. 
The above and other drugs can be present in the reservoir 
alone, or in combination form With pharmaceutical carriers. 
The pharmaceutical carriers acceptable for the purpose of 
this invention are the art knoWn carriers that do not 
adversely affect the drug, the host, or the material compris 
ing the drug delivery device. Suitable pharmaceutical car 
riers include sterile Water, saline, dextrose, dextrose in Water 
or saline, condensation products of castor oil and ethylene 
oxide combining about 30 to about 35 moles of ethylene 
oxide per mole of castor oil, liquid acid, loWer alkanols, oils 
(such as corn oil, peanut oil, sesame oil and the like), With 
emulsi?ers such as mono- or di-glyceride of a fatty acid or 
a phosphatide (e.g., lecithin and the like), glycols, poly 
alkyne glycols, aqueous media in the presence of a suspend 
ing agent (for example, sodium carboxymethylcellulose), 
sodium alginate, poly(vinylpyrolidone), and the like (alone 
or With suitable dispensing agents such as lecithin), or 
polyoxyethylene stearate and the like. The carrier may also 
contain adjuvants such as preserving, stabiliZing, Wetting, 
emulsifying agents and the like together With the penetration 






By “e?‘ective amount, therapeutic amount, therapeu 
tic e?‘ective amount” or “e?‘ective dose” is meant that the 
amount su?icient to elicit the desired pharmacological or 
therapeutic e?‘ect, thus resulting in e?‘ective prevention or 
treatment of the condition or disorder. Thus, When treating 
a CNS disorder, an effective amount of compound is that 
amount su?icient to pass across the blood-brain barrier of 
the subject to interact With relevant receptor sites in the brain 
of the subject. Prevention of the condition or disorder is 
manifested by delaying the onset of the symptoms of the 
condition or disorder. Treatment of the condition or disorder 
is manifested by a decrease in the symptoms associated With 
the condition or disorder, or an amelioration of the recur 
rence of the symptoms of the condition of disorder. 
The e?‘ective dose can vary, depending upon factors such 
as the condition of the patient, the severity of the symptoms 
of the disorder, age, Weight, metabolic status, concurrent 
medications, and the manner in Which the pharmaceutical 
composition is administered. Typically, the e?‘ective dose of 
compounds generally requires administering the compound 
in an amount of about 0.1 to 500 mg/kg of the subject’s 
Weight. In an embodiment of the present invention, a dose of 
about 0.1 to about 300 mg/kg is administered per day 
inde?nitely or until symptoms associated With the condition 
or disorder cease. Preferably, about 1.0 to 50 mg/kg body 
Weight is administered per day. The required dose is less 
When administered parenterally. 
EXAMPLE 1 
The Maximal Electroshock SeiZure (MES) or Maximal 
SeiZure Pattern Test 
The MES is an experimental model for generaliZed tonic 
clonic seiZures that identi?es compounds that prevent sei 
Zure spread. The MES model is highly reproducible and has 
a consistent endpoint. An advantage of this model is that the 
behavioral and electrographic seiZures are consistent With 
those observed in humans [2]. 
In the MES test, the animal receives an electrical stimu 
lus, 0.2 seconds in duration, via corneal electrodes primed 
With an electrolyte solution containing an anesthetic agent. 
The 0.2 second stimulation is generated With 150 mA in rats 
and 50 mA in mice at 60 HZ. Rats, Weighing betWeen 105 g 
and 130 g, and mice, Weighing betWeen 18 g and 25.5 g, 
receive an electrical stimulus 15 minutes, 30 minutes, 1 
hour, 2 hours, and 4 hours after administration of the test 
compound. In rats, the compound is administered orally, 
While mice receive the agent via intraperitoneal injection. 
The test endpoint, electrogenic seizure, is manifested as 
hindlimb tonic extension. Inhibition of hindlimb tonic exten 
sion indicates that the test compound is able to inhibit 
MES-induced seiZure spread and therefore may have anti 
seiZure activity [2-4]. The results of the MES test suggest 
that this class of compounds is e?‘ective in preventing 
seiZure spread in both rats and mice (Tables 1 and 2). 
TABLE 1 
Percentage of mice in Which 30, 100, or 300 mg/kg of the 
test compound prevented MES-induced seizure 0.5 or 
4 hours after intraperitoneal administration. 
0.5 h 4.0 h 
Test Compound (%) (%) 
4,4'—thiodianiline 
30 mg/kg 0 0 
100 mg/kg 66 100 
300 mg/kg 100 100 
US 7,226,949 B2 
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TABLE l-continued 
Percentage of mice in Which 30, 100, or 300 mg/kg of the 
test compound prevented MES-induced seizure 0.5 or 
8 
TABLE 3-continued 
ED5O required to inhibited MES-induced seizure at 
the time of peak effect in rat after oral administration 
4 hours after intraperitoneal administration. 5 of the test compound 
0.5 h 4.0 h Time to Peak Effect ED5O 
Test Compound (%) (%) Test Compound (hours) (mg/kg) 
4,4'—methylenedianiline (3—aminophenyl)- 2 31.74 1 24.42 
10 (4-aminophenyl) amine 
30 mg/kg 0 0 
100 mg/kg 100 0 
300 mg/kg 100 100 
4,4'—diaminobenzophenone EXAMPLE 2 
30 mg/kg 0 0 15 
100 {Hg/kg 100 100 6 Hz Kindling Model 
300 mg/kg 100 100 _ _ _ _ _ 
4,4'-dia_minodiphenyl ether The 6 Hz k1ndl1ng model 15 another experimental se1zure 
model that effectively detects compounds With anti-seizure 
30 mg/kg 0 0 activity. This screen is used to evaluate the ability of a 
100 mg/kg 100 100 20 . . . . I . 
300 {Hg/kg 100 100 compound to prevent the acqu1s1t1on of focal selzures, 1n 
(3_aminophenyl)_ particular, the capacity of a compound to prevent the devel 
(4-aminophenyl) amine opment of seizures induced by a low-frequency (6 Hz), long 
duration (three seconds) stimulus in electrode implanted rats 
138 251;: 108 108 25 is evaluated [5]. Several of the most promising compounds 
300 mg/kg 100 100 Were evaluated in this screen to further characterize their 
anti-seizure activity. 
In the 6 Hz kindling test, mice are implanted With corneal 
TABLE 2 electrodes. The test compound is administered (i.p.) to the 
30 animal at 0.25, 0.5, 1, 2, or 4 hours prior seizure induction. 
Pmmtag? of rats in which 30 {mg/kg of th? Est The seizure is initiated by delivering a current (32 mA at 6 
compound prevented MES-induced seizure 0.25, Hz for three seconds) to the animal through the corneal 
0-5 1-0 2-0 or 4-0 hours aim Oral administration electrodes. The resulting psychomotor seizure is usually 
Test Compound 025 h OIS h 10 h ZIO h 4I0 h characterized by a mrmmal Iclon1c phase followed by ste 
(30 {mg/kg) (%) (%) (%) (%) (%) 35 reotyped, automat1st1c behavlors. ThlS response is analogous 
I I I I to the aura of human patients With partial seizures. If the 
4’4'?nodlamhn? . . 100 100 100 100 100 animal does not exhibit this behavior, the test compound is 
4,4'—methylened1an1l1ne 100 75 92 100 50 . . . 
4I4._diaminob?nzoph?nom 50 100 75 100 75 cons1dered to have protected the ammal and have ant1 
4,4'—diaminodiphenyl ether 100 100 75 75 100 Se1Zl1I'e properties. 
gi'?i?gp?z?yg'mme 0 50 75 50 50 40 The data in Table 4 clearly indicates the capacity of 
p y 4,4'-thiodianiline, 4,4'-diaminobenzophenone, and 4,4'-me 
thylenedianiline to inhibit 6 Hz seizures. 4,4'-Thiodianiline 
A full dose-response curve Was also generated in rats to Was the most e?ecnve Compound evaluated’ havlng an EDso 
determine the ED5O value (n:8 at each time point). These 45 game get?veen 30 anddso dgse 9f 109 211% 
experiments Were conducted at the compound’s time of peak our 0, t e Compoun S teste 1 He selzure 1n _ _ 0 O 
. . . . the ammals tested 0.25, 0.5 and 1.0 hours after admlmstra 
pharmacodynamrc act1v1ty and the results are shown in . | _ _ _ _ non of the compound. 
Table 3. 4,4 -D1am1nod1phenyl ether Was the most active 
compound (EDSO: 5.24:4.67 mg/kg) and also had the long- TABLE 4 
est t1me to peak effect (6 hours). The ED5O of 4,4'-th1od1- 50 
aniline Was evaluated in both rats and mice. In rats, 1 hour P?rc?nmg6 of Mm in Which Exposure to th? T?st Compound 
. . . ' . . . . Prevented Seizure in the 6 Hz Test at 0.25, 0.5, 1.0, 2.0 and 
after oral admrmstratron, 4,4 -th1od1an1l1ne had an EDsoIof 4I0 Hours a?er intmperitoneal Admini nation 
6.60:5.07 mg/kg, and 0.5 hours after mtrapentoneal adm1n 
istration in mice it had an ED5O of 5342:1492 mg/kg. 0'25 h 0'5 h 1'0 h 2'0 h 4'0 h 
55 Test Compound (%) (%) (%) (%) (%) 
TABLE 3 4,4'-thiodianiline 
ED5O required to inhibited MES-induced seizure at 30 mgkg 0 25 25 25 ND 
the time of peak effect in rat after oral administration 80 mgkg 100 100 100 75 0 
of the Est compound 100 mg/kg 100 100 100 100 0 
60 , . . 4,4 —d1am1nobenzophenone 
Time to Peak Effect ED5O 
Test Compound (hours) (mg/kg) 30 mgkg 0 0 0 ND ND 
100 mg/kg 100 100 100 0 0 
4,4'—thiodianiline 1 6.60 r 5.07 4,4'—diaminodiphenyl ether 
4,4'—methylenedianiline 1 10.63 1 5.88 
4,4'-diaminobenzophenone 1 7.15 r 1.89 65 30 mgkg 0 50 25 25 ND 
4,4'—diaminodiphenyl ether 6 5.24 r 4.67 100 mgkg 100 100 100 100 0 
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TABLE 4-continued 
Percentage of Mice in which Exposure to the Test Compound 
Prevented Seizure in the 6 Hz Test at 0.25, 0.5, 1.0, 2.0 and 
4.0 Hours after intraperitoneal Administration 
0.25 h 0.5 h 1.0 h 2.0 h 4.0 h 
Test Compound (%) (%) (%) (%) (%) 
4,4'—methylenedianiline 
30 mg/kg 0 0 0 ND ND 
100 mg/kg 100 100 100 0 0 
EXAMPLE 3 
Hippocampal Kindling Model 
The hippocampal kindling model is an experimental sei 
zure model used to simulate focal seizures. This model 
evaluates the capacity of a compound to affect both the 
expression and acquisition of focal seizures. In addition, 
kindled seizures provide a methodology for studying com 
plex brain networks that may contribute to the spread and 
generalizations of seizures from a focus. The hippocampal 
kindling model has the advantage of being one of the only 
kindling models that can evaluate the temporal effects of an 
agent in a single animal [6,7]. For this assessment, bipolar 
electrodes are surgically implanted in the ventral hippocam 
pus of adult male Sprague-Dawley rats (275-300 g) under 
ketamine-xylazine anesthesia. Following a one-week recov 
ery period, stage ?ve behavioral seizures are induced by 
stimulating the rat 12 times per day with 50 Hz, 10 5 train 
of 1 ms biphasic 200 [1A pulses delivered every 30 min for 
six hours on alternating days. After ?ve stimulus days, the 
animal has had 60 stimulations. A drug free control period 
with supramaximal stimulations is used to verify the stabil 
ity of a stage ?ve generalized seizure before the anticon 
vulsant activity of a drug is measured. 
This screen is used to measure the capacity of the drug to 
prevent the expression of focal seizures. During a drug trial, 
the afterdischarge threshold of each animal is determined by 
increasing the current intensity, stepwise, until the rat dis 
plays an electrographic afterdischarge lasting at least four 
seconds. The animal is exposed to an initial stimulation of 20 
[1A, the stimulation is increased in 10 uA increments every 
one-two minutes until an afterdischarge is recorded. After 
the stability of the stage ?ve seizure is established, the drug 
candidate is administered to the rats via intraperitoneal 
injection 15 minutes after the last control stimulation. Start 
ing with the ?rst dose, the anticonvulsant activity of the test 
agent is measured every thirty minutes for four hours. 
Following each stimulation, Racine seizure scores and after 
discharge durations [8] are compared to control values to 
quantify the anti-convulsant activity of the agent. The 
Racine seizure scores vary from stage 1 to 5. The stages are 
characterized according to the following criteria: Stage 
limouth and facial clonus, Stage 2istage 1 and head 
nodding, Stage 3istage 2 and forelimb clonus, Stage 
4istage 3 and rearing, Stage 5istage 4 and repeated 
rearing and falling [8]. Since a single animal is used, each rat 
serves as its own control. 
4,4'-Thiodianiline was used in the rat hippocampal 
kindled rats to screen to measure its anticonvulsant poten 
tial. Doses of 12.5, 25, 50 and 100 mg/kg were evaluated at 
a minimum of seven time points (n:7 for each dose and each 
time point). Table 5 shows the raw data from a 100 mg/kg 
dose of 4,4'-thiodianiline. After oral administration of the 
test compound stimulation, the Racine seizure scores and 







below. The Racine seizure scores dropped from between a 
stage 4 and stage 5 seizure for control measurements to 
between a stage 1 and stage 2 seizure after treatment with 
4,4'-thiodianiline. 
TABLE 5 
Racine Seizure Scores and Afterdischarge Durations 
Following Stimulation, for Rats Treated with 100 mgkg 
of4 4'—Thiodianiline. 
Racine Seizure Afterdischarge Duration 
Time (min) Score 1 SEM (sec) 1 SEM 
Control 4.86 z 0.14 72.57 1 7.20 
15 1.43 z 081* 19.14 1 9.58* 
45 1.29 z 084* 25.29 :13.71* 
75 0.71 z 0.57* 24.86 1 11.43* 
105 1.29 z 0.64* 33.29 :14.17* 
135 1.57 z 081* 34.71 :14.35* 
165 1.57 z 0.65* 57.43 1 18.17 
195 1.57 z 0.69* 55.29 1 18.19 
225 1.86 z 0.70* 71.29 1 18.99 
255 1.86 z 0.63* 65.43 1 17.91 
*Signi?cantly different than control 
Using the data generated from each of the doses, 4,4' 
thiodianiline, was found to have an ED5O of 51.43 mg/kg. 
This is the dose of 4,4'-thiodianiline required to prevent the 
expression of focal seizures in this model. The capacity of 
4,4'-thiodianiline to elevate afterdischarge threshold and 
decrease afterdischarge duration suggests that it possess the 
ability to limit focal seizure activity originating from the 
ventral hippocampus. 
4,4'-Diaminobenzanalide and 4,4'-diaminodiphenyl ether 
were also evaluated in the hippocampal kindling model. 
While these compounds were not as effective as 4,4'-thio 
dianiline, they also had the capacity to block the expression 
of fully kindled seizures. 
EXAMPLE 4 
Minimal Neurotoxicity 
Toxicity in mice and rats is assessed using three screens: 
the rotorod in mice, positional sense and gait in rats. In mice, 
the test compound is administered at doses of 30, and 100 
mg/kg prior to evaluation in the toxicity screens. The mice 
are tested at 0.5 hours and 4 hours after intraperitoneal 
administration of the test compound. In rats, the test com 
pound is administered at 30 mg/kg prior to the toxicity 
assessment. The rats are tested at 0.25, 0.5, 1, 2, and 4 hours 
after oral administration of the test compound. In rats, a 
series of doses were tested at the time to peak effect to 
determine the toxicity ED5O at this timepoint. 
Rotorod Test 
Toxicity in mice weighing between 18 and 25.5 g is 
assessed using the standardized rotorod test [9]. For each 
compound tested, a minimum of 18 animals are evaluated 
for neurotoxicity. Control mice can maintain their equilib 
rium for an extended period of time when they are placed on 
a 6-rpm rotation rod. Neurologically impaired animals can 
not maintain equilibrium for one minute in each of three 
successive trials. 
Positional Sense Test 
Behavioral toxicity in twenty rats weighing between 105 
and 130 g is assessed by the positional sense test. In this test, 
one hind leg is gently lowered over the edge of a table. If the 
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rat experiences neurological toxicity, it Will not be able to 
quickly lift its leg quickly back to a normal position. 
Gait and Stance Test 
In the gait and stance test, neurotoxicity is indicated by a 
circular or zigzag gait after administration of the test com 
pound. In addition, ataxia, abnormal spread of the legs, 
abnormal posture, tremor hyperactivity, lack of exploratory 
behavior, somnolence, stupor, or catalepsy can indicate 
neurotoxicity. This toxicity test Was conducted on rats, 
Weighing betWeen 105 and 130 g. 
The acute neurotoxicity of this class of compounds Was 
shoWn to be Well above the doses required for therapeutic 
bene?t. No acute neurotoxicity Was observed as measured 
by the rotorod test up to four hours after mice had been given 
4,4'-thiodianiline, even at doses as high as 300 mg/kg. In 
rats, 1 hour (the time to peak effect) after oral administration 
of 4,4'-thiodianiline, the ED5O for toxicity Was determined to 
be almost 60 times greater than the ED5O for anti-convulsant 
activity. Similarly, 4,4'-diaminobenzophenone Was not neu 
rotoxic to rats. None of the rats tested at any timepoints (0.25 
to 24 hours after oral administration of 4,4'-diaminoben 
zophenone) shoWed acute neurotoxic elfects, even at doses 
as high as 500 mg/kg. In contrast, the ED5O for anti 
convulsant activity for 4,4'-diaminobenzophenone in rats 
Was 7.15 mg/kg. In mice, 4,4'-diaminobenzophenone 
shoWed no neurotoxicity at doses beloW 100 mg/kg. 4,4' 
Diaminodiphenyl ether, 4,4'-methylenedianiline and (3-ami 
nophenyl)-(4-aminophenyl) amine had no signi?cant toxic 
ity even at 100 mg/kg in mice and 250 mg/kg in rats. 
These data suggest that the acute neurotoxicity levels of 
these compounds in mice and rats, as assessed by the rotorod 
test, the positional sense and the gait and stance tests, far 
exceed the level required for anticonvulsant activity. 
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While the salient features have been illustrated and 
described With respect to particular embodiments, it should 
be readily apparent that modi?cations can be made Within 
the spirit and scope of the invention, and it is therefore not 
desired to limit the invention to the exact details shoWn and 
described. 
What is claimed is: 
1. A method of treating and ameliorating epilepsy, seizure 
or electroconvulsive disorders in mammals Which comprises 
administering a therapeutic effective amount to said mam 
mal of the folloWing therapeutic compound, including 
resolved enantiomers, diastereomers, salts, solvates and 
polymorphic froms thereof, having the folloWing formula 
(1)1 
X 
Rt I \ / )3 
N—| I—N 
RZ/ / \ \R4 
Wherein 
R1, R2, R3, and R4, are each independently selected from 
the group consisting of hydrogen, hydroxy, amino, 
phenyl, a substituted or unsubstituted Cl_1O alkyl, C3_1O 
branched alkyl, a substituted or unsubstituted C3_8 
cycloalkyl, a substituted or unsubstituted arylalkyl, a 
substituted or unsubstituted C HO alkoxyl and a substi 
tuted or unsubstituted Cl_1O acyl; and 
X is selected from the group consisting of 40*, iSi, 
(I) 
Oi, iN(H)Si, iS(O)i, iSOZ, iPO4i, iSi 
(O)i, iC(O)i, iCH2i, 4CF2i, and a covalent 
bond. 
2. The method of claim 1, Wherein the substituted or 
unsubstituted arylalkyl is Ar-(CH2)n; Wherein Ar is an aro 
matic ring and n is from 1 to 10. 
3. The method of claim 2, Wherein the substituents of the 
substituted groups are selected from the group consisting of 
halogen, phenyl, thio, amino, hydroxyl, hydroxylamino, 
nitrile, carboxyl, amido, phosphate, sulfate, sulfonamide, 
nitroso, nitrone, azido, imino, hydrazine, guanidino, 
oxyguanidino, methylguanidino, hydroxyguanidino, ami 
noguanidino, thioguanidino, amidino, oxyamidino, ureido, 
thioureido, thioamido and nitro. 
4. The method of claim 1, Wherein the compound is 
selected form the group consisting of 4,4'-thiodianiline, 
4,4'-diaminobenzophenone, 4,4'-diaminodiphenyl ether, 4,4 
methylenedianiline, and (3-aminophenyl)-(4-aminophenyl) 
amine. 
5. The method of claim 1, Wherein the compound is 
4,4'-thiodianiline. 
6. The method of claim 1, Wherein the compound is 
4,4'-diaminobenzophenone. 
7. The method of claim 1, Wherein the compound is 
4,4'-diaminodiphenyl ether. 
8. The method of claim 1, Wherein the compound is 
4,4'-methylenedianiline. 
9. The method of claim 1, Wherein the compound is 
(3-aminophenyl)-(4-aminophenyl) amine. 
10. The method of claim 1, Wherein the therapeutic 
effective amount is from about 0.1 mg/kg to about 300 
mg/kg. 
11. The method of claim 1, Wherein the therapeutic 
effective amount is from about 1 mg/kg to about 40 mg/kg. 
* * * * * 
